학술논문
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Document Type
Article
Author
Craig, Timothy J ; Reshef, Avner; Li, H Henry; Jacobs, Joshua S; Bernstein, Jonathan A; Farkas, Henriette; Yang, William H; Stroes, Erik S G; Ohsawa, Isao; Tachdjian, Raffi; Manning, Michael E; Lumry, William R; Saguer, Inmaculada Martinez; Aygören-Pürsün, Emel; Ritchie, Bruce; Sussman, Gordon L; Anderson, John; Kawahata, Kimito; Suzuki, Yusuke; Staubach, Petra; Treudler, Regina; Feuersenger, Henrike; Glassman, Fiona; Jacobs, Iris; Magerl, Markus
Source
In The Lancet
Subject
Language
ISSN
0140-6736